New insider activity at BioAge Labs, Inc. ( (BIOA) ) has taken place on March 11, 2025.
Shane Barton, the Vice President and Corporate Controller at BioAge Labs, Inc., has made a significant investment by purchasing 2,632 shares of the company’s stock. This transaction is valued at $47,376, indicating a strong vote of confidence in the company’s future prospects.
Recent Updates on BIOA stock
Recent developments surrounding BioAge Labs, Inc. have led to changes in analyst ratings and price targets. Morgan Stanley assumed coverage with an Underweight rating and a price target reflecting concerns over the recent discontinuation of their lead program, azeleprag. This decision was influenced by the early-stage nature of the remaining pipeline and the need for greater clarity on future developments. Additionally, William Blair initiated coverage with a Market Perform rating, balancing the company’s innovative potential against competitive and developmental challenges. These changes come amid a backdrop of a class action lawsuit, which adds to the uncertainty surrounding the company’s future prospects.
More about BioAge Labs, Inc.
YTD Price Performance: -18.17%
Average Trading Volume: 537,106
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $163.1M